Drug:
Reaction: WRONG TECHNIQUE IN PRODUCT USAGE PROCESS
20250101 - 20251231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 25491833 |
US |
65 | 1 |
Wrong technique in product usage process, |
||||
PEGFILGRASTIM, |
||||
| 2 | 25491839 |
US |
68 | 2 |
Pain in extremity, Wrong technique in product usage process, Product administered at inappropriate site, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 3 | 25491858 |
US |
1 | |
Wrong technique in product usage process, Device mechanical issue, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 4 | 25491985 |
US |
||
Wrong technique in product usage process, Product prescribing issue, |
||||
RILUZOLE, |
||||
| 5 | 25492005 |
US |
||
Wrong technique in product usage process, Off label use, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 6 | 25492053 |
US |
56 | |
Wrong technique in product usage process, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, TIZANIDINE, GABAPENTIN, LOSARTAN, |
||||
| 7 | 25492081 |
US |
35 | |
Drug dose omission by device, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 8 | 25492148 |
US |
62 | |
Wrong technique in product usage process, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 9 | 25492175 |
US |
58 | 1 |
Wrong technique in product usage process, |
||||
EDARAVONE, EDARAVONE, EDARAVONE, EDARAVONE, |
||||
| 10 | 25492193 |
US |
64 | 2 |
Headache, Incorrect dose administered, Wrong technique in product usage process, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 11 | 25492210 |
US |
2 | |
Wrong technique in product usage process, Product use complaint, |
||||
MEMANTINE, MEMANTINE HYDROCHLORIDE, |
||||
| 12 | 25492213 |
US |
2 | |
Wrong technique in product usage process, |
||||
MEMANTINE, MEMANTINE HYDROCHLORIDE, |
||||
| 13 | 25492226 |
US |
54 | |
Wrong technique in product usage process, Product preparation error, Wrong technique in device usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 14 | 25492241 |
US |
58 | |
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 15 | 25492274 |
US |
65 | 2 |
Wrong technique in product usage process, Liquid product physical issue, Product label issue, |
||||
TRIAMCINOLONE ACETONIDE, |
||||
| 16 | 25492282 |
SI |
5 | 2 |
Adrenal insufficiency, Wrong technique in product usage process, |
||||
MOMETASONE, METHYLPREDNISOLONE, METHYLPREDNISOLONE, DESLORATADINE, OLOPATADINE, |
||||
| 17 | 25492326 |
US |
71 | 1 |
Wrong technique in product usage process, Product administration error, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, AMLODIPINE, BISOPROLOL FUMARATE, ESOMEPRAZOLE MAGNESIUM, |
||||
| 18 | 25492362 |
US |
65 | |
Wrong technique in product usage process, Product administered at inappropriate site, Accidental underdose, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 19 | 25492455 |
US |
2 | |
Injury associated with device, Device difficult to use, Wrong technique in product usage process, |
||||
DENOSUMAB, |
||||
| 20 | 25492485 |
US |
77 | 2 |
Wrong technique in product usage process, Feeling abnormal, Drug delivery system malfunction, |
||||
TOCILIZUMAB, LEVOTHYROXINE, MONTELUKAST SODIUM, PREDNISONE, |
||||
| 21 | 25492552 |
US |
||
Dyspnoea, Drug dose omission by device, Wrong technique in product usage process, Incorrect dose administered by device, Device issue, Device deposit issue, Device delivery system issue, |
||||
ALBUTEROL SULFATE, |
||||
| 22 | 25492655 |
US |
69 | |
Wrong technique in product usage process, Device deposit issue, Device occlusion, No adverse event, |
||||
ALBUTEROL SULFATE, MORPHINE, |
||||
| 23 | 25492747 |
US |
2 | |
Kidney infection, Device infusion issue, Somnolence, Inappropriate schedule of product administration, Memory impairment, Muscular weakness, Oropharyngeal pain, Infusion site mass, Migraine, Hypersensitivity, COVID-19, Illness, Wrong technique in product usage process, Abdominal discomfort, Malaise, Fatigue, |
||||
| 24 | 25493007 |
US |
63 | 2 |
Injury associated with device, Product administered at inappropriate site, Wrong technique in product usage process, Incorrect dose administered, Injection site swelling, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 25 | 25493089 |
US |
67 | 2 |
Micturition frequency decreased, Wrong technique in product usage process, Fatigue, |
||||
SPARSENTAN, |
||||
| 26 | 25493096 |
US |
24 | 2 |
Off label use, Wrong technique in product usage process, |
||||
SPARSENTAN, |
||||
| 27 | 25493514 |
US |
2 | |
Accidental exposure to product, Wrong technique in product usage process, |
||||
FLUTICASONE PROPIONATE AND SALMETEROL, |
||||
| 28 | 25493723 |
US |
64 | 2 |
Wrong technique in product usage process, Product dispensing error, |
||||
INSULIN LISPRO, INSULIN LISPRO, INSULIN GLARGINE, |
||||
| 29 | 25494105 |
US |
87 | 2 |
Visual impairment, Device difficult to use, Drug dose omission by device, Wrong technique in product usage process, |
||||
EVOLOCUMAB, |
||||
| 30 | 25494198 |
15 | ||
Wrong technique in product usage process, Off label use, |
||||
RUXOLITINIB, |
||||
| 31 | 25494260 |
US |
2 | |
Asthma, Dyspnoea, Drug dose omission by device, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 32 | 25494303 |
US |
73 | 1 |
Influenza like illness, Instillation site discharge, Wrong technique in product usage process, |
||||
NADOFARAGENE FIRADENOVEC-VNCG, |
||||
| 33 | 25494335 |
US |
87 | 1 |
Urine output decreased, Urge incontinence, Dysuria, Wrong technique in product usage process, |
||||
NADOFARAGENE FIRADENOVEC-VNCG, NADOFARAGENE FIRADENOVEC-VNCG, |
||||
| 34 | 25494426 |
US |
1 | |
Product dose omission issue, Wrong technique in product usage process, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 35 | 25494491 |
US |
1 | |
Wrong technique in product usage process, |
||||
SPARSENTAN, |
||||
| 36 | 25494584 |
US |
2 | |
Wrong technique in product usage process, Device defective, |
||||
ESTRADIOL AND LEVONORGESTREL, |
||||
| 37 | 25494762 |
US |
1 | |
Wrong technique in product usage process, |
||||
SPARSENTAN, |
||||
| 38 | 25494909 |
SI |
5 | 2 |
Adrenal insufficiency, Wrong technique in product usage process, |
||||
MOMETASONE FUROATE, MOMETASONE, METHYLPREDNISOLONE, METHYLPREDNISOLONE, DESLORATADINE, OLOPATADINE, HYDROCHLOROTHIAZIDE, |
||||
| 39 | 25494948 |
US |
30 | 1 |
Feeling abnormal, Wrong technique in product usage process, |
||||
SPARSENTAN, |
||||
| 40 | 25494968 |
US |
1 | |
Dysphagia, Wrong technique in product usage process, |
||||
OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 41 | 25495005 |
US |
56 | 1 |
Wrong technique in product usage process, Product adhesion issue, |
||||
| 42 | 25495096 |
BR |
72 | 1 |
Urinary tract infection, Aspiration, Pneumonia, Off label use, Wrong technique in product usage process, |
||||
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE, |
||||
| 43 | 25495107 |
US |
61 | 1 |
Wrong technique in product usage process, Liquid product physical issue, |
||||
TRIAMCINOLONE ACETONIDE, |
||||
| 44 | 25495233 |
US |
2 | |
Wrong technique in product usage process, Injection site haemorrhage, |
||||
ADALIMUMAB, |
||||
| 45 | 25495693 |
US |
73 | 2 |
Abdominal pain upper, Rash pruritic, Vision blurred, Injection site pain, Wrong technique in product usage process, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 46 | 25495701 |
US |
1 | |
Neurodermatitis, Rebound effect, Wrong technique in product usage process, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 47 | 25496189 |
US |
||
Wrong technique in product usage process, Muscle spasms, |
||||
RUXOLITINIB, ACYCLOVIR, CALCIUM CARBONATE, CETIRIZINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE, ESTRADIOL, FAMOTIDINE, KENALOG, |
||||
| 48 | 25496661 |
US |
62 | 1 |
Wrong technique in product usage process, Product administered at inappropriate site, Underdose, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 49 | 25491528 |
US |
||
Wrong technique in product usage process, |
||||
LINACLOTIDE, |
||||
| 50 | 25491620 |
US |
2 | |
Asthenopia, Ocular hyperaemia, Lacrimation increased, Eye pain, Burning sensation, Ocular discomfort, Foreign body sensation in eyes, Condition aggravated, Wrong technique in product usage process, Liquid product physical issue, Off label use, |
||||
PERFLUOROHEXYLOCTANE, |
||||
| 51 | 25490164 |
US |
||
Dyspnoea, Drug dose omission by device, Wrong technique in product usage process, Wrong technique in device usage process, Circumstance or information capable of leading to device use error, |
||||
ALBUTEROL SULFATE, |
||||
| 52 | 25490170 |
US |
67 | |
Chest discomfort, Drug dose omission by device, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 53 | 25490228 |
US |
40 | |
Drug dose omission by device, Wrong technique in product usage process, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 54 | 25490229 |
US |
46 | |
Dyspnoea, Wheezing, Cough, Drug dose omission by device, Device delivery system issue, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 55 | 25490230 |
US |
52 | |
Dyspnoea, Drug dose omission by device, Wrong technique in product usage process, Device deposit issue, |
||||
ALBUTEROL SULFATE, |
||||
| 56 | 25490356 |
US |
68 | |
Wheezing, Breath sounds abnormal, Drug dose omission by device, Wrong technique in product usage process, Product use in unapproved indication, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, LISINOPRIL, |
||||
| 57 | 25490423 |
US |
49 | |
Dyspnoea, Chest discomfort, Abdominal discomfort, Drug dose omission by device, Wrong technique in product usage process, Wrong technique in device usage process, |
||||
ALBUTEROL SULFATE, PREDNISONE, |
||||
| 58 | 25490642 |
US |
72 | |
Drug dose omission by device, Dyspnoea, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, NIFEDIPINE, HYDRALAZINE HYDROCHLORIDE, CARVEDILOL, FUROSEMIDE, CINACALCET, |
||||
| 59 | 25486397 |
US |
||
Wrong technique in product usage process, |
||||
EVEROLIMUS, |
||||
| 60 | 25486496 |
US |
2 | |
Hip arthroplasty, Wrong technique in product usage process, |
||||
SEMAGLUTIDE, |
||||
| 61 | 25486503 |
US |
87 | 1 |
Blood pressure abnormal, Wrong technique in product usage process, |
||||
SEMAGLUTIDE, SEMAGLUTIDE, |
||||
| 62 | 25486522 |
US |
71 | 2 |
Device difficult to use, Product administration error, Wrong technique in product usage process, Illness, Blood cholesterol decreased, |
||||
EVOLOCUMAB, EVOLOCUMAB, ADALIMUMAB, |
||||
| 63 | 25486806 |
FR |
21 | 2 |
Psychiatric decompensation, Catatonia, Wrong technique in product usage process, Off label use, |
||||
| 64 | 25487120 |
US |
60 | |
Dyspnoea, Drug dose omission by device, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, |
||||
| 65 | 25487159 |
US |
15 | |
Drug dose omission by device, Wrong technique in product usage process, Device difficult to use, Product use issue, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 66 | 25487238 |
US |
50 | 1 |
Petechiae, Device mechanical issue, Wrong technique in product usage process, |
||||
ADALIMUMAB-ADBM, |
||||
| 67 | 25487308 |
US |
2 | |
Product storage error, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, |
||||
| 68 | 25487324 |
US |
67 | |
Dyspnoea, Drug dose omission by device, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 69 | 25487350 |
US |
55 | |
Dyspnoea, Malaise, Irritability, Drug dose omission by device, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 70 | 25487393 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 71 | 25487445 |
US |
||
Abnormal dreams, Nightmare, Wrong technique in product usage process, |
||||
LEVOCETIRIZINE DIHYDROCHLORIDE, |
||||
| 72 | 25487496 |
US |
||
Loss of consciousness, Limb injury, Joint injury, Headache, Vision blurred, Hordeolum, Wrong technique in product usage process, |
||||
LOTILANER OPHTHALMIC SOLUTION, ERYTHROMYCIN, MONTELUKAST, PREDNISONE, MYCOPHENOLIC ACID, MYCOPHENILIC ACID, PYRIDOSTIGMINE BROMIDE ORAL, ERGOCALCIFEROL, |
||||
| 73 | 25487601 |
US |
82 | |
Wrong technique in product usage process, Off label use, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, TIOTROPIUM BROMIDE, |
||||
| 74 | 25487625 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
VARENICLINE, VARENICLINE TARTRATE, |
||||
| 75 | 25487776 |
US |
||
Wrong technique in product usage process, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 76 | 25487873 |
PH |
62 | 1 |
Gastritis erosive, Heart failure with reduced ejection fraction, Atrial fibrillation, Ischaemic cardiomyopathy, Type 2 diabetes mellitus, Upper respiratory tract infection, Tendonitis, Reflux laryngitis, Oesophagitis, Hiatus hernia, Cardiovascular disorder, Hyperuricaemia, Cholelithiasis, Wrong technique in product usage process, |
||||
SACUBITRIL AND VALSARTAN, PANTOPRAZOLE, DAPAGLIFLOZIN, |
||||
| 77 | 25488021 |
US |
63 | |
Dyspnoea, Drug dose omission by device, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, |
||||
| 78 | 25488143 |
US |
61 | 2 |
Underdose, Wrong technique in product usage process, |
||||
TIRZEPATIDE, |
||||
| 79 | 25488185 |
US |
2 | |
Crohn^s disease, Wrong technique in product usage process, Stress, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 80 | 25488348 |
US |
63 | |
Dysphonia, Asthma, Drug dose omission by device, Device deposit issue, Wrong technique in product usage process, Device occlusion, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 81 | 25488455 |
US |
22 | 2 |
Device adhesion issue, Wrong technique in product usage process, |
||||
ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, |
||||
| 82 | 25488562 |
US |
15 | |
Drug dose omission by device, Wrong technique in product usage process, Device use issue, Device issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 83 | 25488660 |
US |
||
Breast tenderness, Heavy menstrual bleeding, Intermenstrual bleeding, Wrong technique in product usage process, Product use issue, Product use in unapproved indication, |
||||
LEVONORGESTREL/ETHINYL ESTRADIOL, LEVONORGESTREL/ETHINYL ESTRADIOL, |
||||
| 84 | 25488736 |
US |
||
Wrong technique in product usage process, Incorrect dose administered, Product preparation issue, Injection site bruising, |
||||
TESAMORELIN, SEMAGLUTIDE, |
||||
| 85 | 25488896 |
FR |
||
Needle issue, Wrong technique in product usage process, |
||||
| 86 | 25489829 |
DE |
1 | |
Growth retardation, Renal function test abnormal, Cough, Nasopharyngitis, Frequent bowel movements, Dyspepsia, Wrong technique in product usage process, Off label use, |
||||
CAPMATINIB, |
||||
| 87 | 25490757 |
US |
81 | |
Wrong technique in product usage process, No adverse event, |
||||
CEFADROXIL, LISINOPRIL, BISOPROLOL FUMARATE, ERGOCALCIFEROL, |
||||
| 88 | 25490766 |
US |
1 | |
Injury associated with device, Wrong technique in product usage process, |
||||
ROMOSOZUMAB-AQQG, |
||||
| 89 | 25481453 |
US |
1 | |
Feeling abnormal, Product availability issue, Inappropriate schedule of product administration, Wrong technique in product usage process, |
||||
CLONAZEPAM, |
||||
| 90 | 25481524 |
US |
2 | |
Insomnia, Wrong technique in product usage process, Malaise, Treatment noncompliance, |
||||
CLONAZEPAM, |
||||
| 91 | 25481598 |
TR |
50 | 1 |
Thyroidectomy, Wrong technique in product usage process, |
||||
METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, SEMAGLUTIDE, |
||||
| 92 | 25482163 |
US |
70 | |
Malaise, Dyspnoea, Wrong technique in product usage process, Drug dose omission by device, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 93 | 25482194 |
US |
65 | |
Wrong technique in product usage process, Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, QUETIAPINE, PANTOPRAZOLE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 94 | 25482209 |
US |
39 | |
Wrong technique in product usage process, Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 95 | 25482226 |
US |
64 | |
Device delivery system issue, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 96 | 25482271 |
US |
||
Tremor, Abdominal tenderness, Hereditary angioedema, Abdominal distension, Wrong technique in product usage process, Injection site pain, |
||||
ICATIBANT, |
||||
| 97 | 25482312 |
US |
2 | |
Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, |
||||
| 98 | 25482518 |
US |
9 | 1 |
Product dose omission issue, No adverse event, Wrong technique in product usage process, Product complaint, |
||||
OMALIZUMAB, OMALIZUMAB, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, LORATADINE, LORATADINE TABLET, IPRATROPIUM BROMIDE, EPINEPHRINE, |
||||
| 99 | 25482536 |
US |
||
Wrong technique in product usage process, Liquid product physical issue, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 100 | 25482634 |
US |
2 | |
Pneumonia, Influenza, Norovirus infection, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-07-29